Introduction
============

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the fourth main cause of cancer-related deaths worldwide.[@b1-cmar-10-3697] In recent years, great improvements have been made in the treatment of HCC, such as in liver transplantation, surgical resection, local ablation, and transcatheter arterial chemoembolization.[@b2-cmar-10-3697],[@b3-cmar-10-3697] However, the 5-year survival rate of HCC is still very low, mainly due to insidious onset of the disease and high rate of tumor recurrence as well as tumor metastasis.[@b4-cmar-10-3697] Therefore, a better understanding of HCC pathogenesis and prognosis prediction is urgently needed to refine the outcomes of HCC patients.

V-set and immunoglobulin domain containing protein 4 (VSIG4), also called CRIg and Z39Ig, is a novel type 1 transmembrane protein of B7-related immunoglobulin superfamily.[@b5-cmar-10-3697],[@b6-cmar-10-3697] The VSIG4 protein, which is mainly distributed in liver, heart, and placenta, is well known for the negative regulation effect of T-cells.[@b7-cmar-10-3697] VSIG4 was proved to be a coinhibitory ligand that negatively regulates T-cell activation through inhibiting CD4^+^ and CD8^+^ T-cell proliferation and IL-2 production.[@b8-cmar-10-3697] Recent studies have confirmed that *VSIG4* gene was overexpressed on several kinds of cancer cells such as lung cancer, ovarian cancer, breast cancer, glioblastoma, and multiple myeloma, and acted as an oncogene that led to the functions of cellular immunity and promotion of tumor progression.[@b9-cmar-10-3697]--[@b13-cmar-10-3697] In the research fields of liver diseases, relative studies have suggested that VSIG4 expressed on Kupffer cells could serve as a protective factor for liver injury.[@b14-cmar-10-3697] However, the expression and biological function of VSIG4 in HCC are still unknown.

The current study aimed to investigate the expression of VSIG4 in HCC and the prognostic significance of VSIG4 in patients with HCC. The bioinformatics analyses demonstrated that *VSIG4* was downregulated in HCC tissues, and low expression level of *VSIG4* was closely related to poor prognosis in hepatitis B virus (HBV)-positive HCC patients. However, *VSIG4* expression has no markedly predictive significance in HBV-negative patients. Moreover, by exploring the *VSIG4* expression in 4 HCC cell lines and 36 pairs of tissue specimens, we further confirmed the low expression of *VSIG4* and its predictive significance for HCC, which were consistent with the bioinformatics analysis.

Materials and methods
=====================

Cell lines and cell culture
---------------------------

Four human hepatoma cell lines (HepG2, SK-hep-1, Huh-7, and MHCC-97H) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, People's Republic of China). The human liver cell line LO2 was obtained from our laboratory, and its use was approved by the ethics committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University (Guangzhou, People's Republic of China). All cell lines were cultured in Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Biological Industries, Haemek, Israel) and 100 units/mL penicillin plus 100 µg/mL streptomycin. All cells were maintained at 37°C in an atmosphere containing 5% CO~2~.

Patients and tumor tissues
--------------------------

HCC tissues and the adjacent normal tissues were collected from 36 patients during hepatectomy for HCC at Sun Yatsen Memorial Hospital from 2016 to 2017. All patients were diagnosed based on the clinical and pathological evidences when being admitted to our center. The tissue specimens were immediately snap frozen in liquid nitrogen after resection from patients and then stored at −80°C. None of the patients received radiotherapy, chemotherapy, or transcatheter arterial chemoembolization or were treated with targeted-drugs such as sorafenib before surgery.

RNA extraction and quantitative reverse transcription polymerase chain reaction (qRT-PCR)
-----------------------------------------------------------------------------------------

Total RNA from tissues or cell lines was extracted with Trizol reagent (Takara, Shiga, Japan) according to the manufacturer's instructions. mRNA was reverse transcribed by using a Prime- Script RT reagent Kit (Takara). cDNA was amplified and quantified on CFX96 system (Bio-Rad, Hercules, CA, USA) using SYBR Premix Ex Taq (Takara). Briefly, PCRs were performed in a final volume of 10 µL, and the thermal conditions were 95°C for 30 seconds followed by 40 cycles of 95°C for 5 seconds and 60°C for 20 seconds. GAPDH was used as endogenous controls. Expression of VSIG4 was determined using the 2^−ΔΔ^*^C^*^T^ method.[@b15-cmar-10-3697] The primers were VSIG4 sense AACCACCATACAGCACAAGCA, antisense CAAGACCAAGACTGAGGCACC; GAPDH sense ACAACTTTGGTATCGTGGAAGG, antisense GCCATCACGCCACAGTTTC.

The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) data
---------------------------------------------------------------------

TCGA database, which contains gene information through large-scale genomic sequencing, is a bank for multidimensional genomic information of 33 types of human cancers. Data including gene expression profiles and clinical information of HCC patients were obtained from the Genomic Data Commons Data Portal within TCGA data portal (<https://portal.gdc.cancer.gov/>). Of 427 TCGA mRNA data samples of liver cancer (377 tumors and 50 normals) downloaded from the database, those samples missing relevant clinical information were eliminated. When this was done, there were 232 samples (182 tumors, 50 normals) left, and those data were analyzed in our study. GEO is another genomics data repository of high-throughput gene expression data including hybridization arrays, chips, and microarrays. One series of gene expression profiling, including gene information of 60 patients with HCC, was downloaded to investigate aberrant gene expression in HCC.

Gene information acquisition and gene screening
-----------------------------------------------

The gene expression profiles of patients with HCC in TCGA were extracted from the database by R software (The R Foundation, Vienna, Austria), and gene expression levels of the samples (Fragments Per Kilobase of transcript per Million \[FPKM\] standardization) were obtained. Fifty patients, whose gene expression profiles included both tumor tissues and matched adjacent normal tissues, were chosen to the next step. The genes with differential expression in HCC were distinguished using the glmnet package of R software. Lasso (least absolute shrinkage and selection operator) regression analysis was performed following known procedures[@b16-cmar-10-3697],[@b17-cmar-10-3697] to further screen the genes to assess if the fold changes of expression between tumor and normal tissues were \>2. Thus, those genes with a better research value for our study were acquired.

Statistical analysis
--------------------

All of the statistical analysis including independent and paired *t*-test, rank sum test, lasso regression analysis, and survival analysis were done using SPSS 22.0 (IBM Corporation, Armonk, NY, USA) and R software. In our study, *p*-value \<0.05 was considered significant.

Ethics approval
---------------

This study was approved by the ethics committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. Informed consent was signed by all the patients whose tissue specimens were used in our study.

Results
=======

Significant difference of VSIG4 expression in tumor and normal tissues
----------------------------------------------------------------------

A number of genes were screened using the glmnet package of R software, based on *p*-value of paired *t*-test and Wilcoxon signed rank test (data not shown). After dimensionality reduction by lasso regression model, the top 30 mRNAs which were considered to have obvious statistical differences of expression in tumor and normal tissues were selected ([Table S1](https://www.dovepress.com/get_supplementary_file.php?f=165822.pdf)). *VSIG4*, the gene that has not been studied in HCC, was one of these selected genes. Also, *VSIG4* showed significant differential expression between tumor and normal tissues, and thus was worth further exploration.

The expression of VSIG4 in HCC, verified by bioinformatics analysis
-------------------------------------------------------------------

The expression of *VSIG4* mRNA was investigated by using the gene expression information of profiles in TCGA and GEO datasets. TCGA data showed that the expression of *VSIG4* was significant lower in 50 HCC tissues, compared with that in 50 matched adjacent tissues (*p*\<0.01) ([Figure 1A](#f1-cmar-10-3697){ref-type="fig"}). Similar results that *VSIG4* expression was downregulated in tumors were obtained by analyzing GSE64041 dataset with 60 pairs of tissue samples (*p*\<0.001) ([Figure 1B](#f1-cmar-10-3697){ref-type="fig"}).

Relevance between VSIG4 expression and clinicopathological characteristics
--------------------------------------------------------------------------

By analyzing the clinicopathological parameters of 182 HCC patients from the TCGA database, univariate analysis revealed that *VSIG4* expression was significantly associated with serum level of AFP (*p*=0.022) and tumor M stage (*p*=0.009) ([Table 1](#t1-cmar-10-3697){ref-type="table"}). But there was no obvious association with other characteristics including age, gender, viral hepatitis infection, Child--Pugh classification, cirrhosis, T and N stages, as well as tumor differentiation (*p*\>0.05). [Figure 1C and D](#f1-cmar-10-3697){ref-type="fig"} shows that low expression level of *VSIG4* was closely related to high serum AFP level (*p*=0.028) and tumor distant metastasis (*p*=0.029).

Correlation between VSIG4 expression and survival of HCC patients
-----------------------------------------------------------------

The survival curves for overall survival (OS) ([Figure 2A](#f2-cmar-10-3697){ref-type="fig"}) and disease-free survival (DFS) ([Figure 2B](#f2-cmar-10-3697){ref-type="fig"}) of 182 HCC patients in TCGA database were plotted. Although the median OS and DFS of patients with high *VSIG4* expression was slightly longer than those with low *VSIG4* expression, Kaplan--Meier analysis showed little relationship between *VSIG4* expression and survival time (*p* all \>0.05). Then, the patients were divided into several subgroups based on clinicopathological parameters including race, clinical stage, tumor histological grade, and viral hepatitis infection. We did not find significant differences between *VSIG4* expression and survival time of patients when sub- divided based on different race, clinical stage, and tumor histological grade (data not shown). But interestingly, in the HBV-positive HCC patients, we found that median OS in high *VSIG4* expression group (1,694 days) was significantly longer than that in the low *VSIG4* expression group (768 days) ([Figure 2C](#f2-cmar-10-3697){ref-type="fig"}). Also, it was demonstrated that patients with low *VSIG4* mRNA level had a shorter DFS ([Figure 2D](#f2-cmar-10-3697){ref-type="fig"}). Univariate analysis also demonstrated that *VSIG4* expression was associated with AFP level and tumor distant metastasis ([Table S2](https://www.dovepress.com/get_supplementary_file.php?f=165822.pdf)). Cox analysis showed that *VSIG4* expression was an independent prognostic factor in HBV-related HCC, for both OS and DFS ([Table S3](https://www.dovepress.com/get_supplementary_file.php?f=165822.pdf)). However, Kaplan--Meier survival curves for OS ([Figure 2E](#f2-cmar-10-3697){ref-type="fig"}) and DFS ([Figure 2F](#f2-cmar-10-3697){ref-type="fig"}) still showed no significant differences in the HBV-negative HCC patients, including in patients with hepatitis C virus (HCV) infection ([Figure S1A and B](https://www.dovepress.com/get_supplementary_file.php?f=165822.pdf)). We also found no significant correlation between *VSIG4* expression and the clinicopathological parameters of HBV-negative HCC patients ([Table S4](https://www.dovepress.com/get_supplementary_file.php?f=165822.pdf)), including those with HCV infection ([Table S5](https://www.dovepress.com/get_supplementary_file.php?f=165822.pdf)).

VSIG4 expression in hepatoma cell lines and surgically removed HCC tissues
--------------------------------------------------------------------------

qRT-PCR assay was conducted to further confirm the phenomenon of *VSIG4* downregulation in HCC. We compared the expression of *VSIG4* in 4 human hepatoma cell lines including HepG2, Sk-hep-1, Huh7, and MHCC-97H, with that in human liver cell strain LO2. As can be seen from [Figure 3D](#f3-cmar-10-3697){ref-type="fig"}, *VSIG4* expression in hepatoma cells was significantly lower than that in normal liver cells (all *p*\<0.001). Then, we explored the mRNA level of *VSIG4* in 36 pairs of HCC and adjacent tissues specimens which were surgically removed from 36 HCC patients in our center. The results of the PCR assay showed low expression of *VSIG4* in 86.1% (31/36) HCC specimens, compared with matched adjacent specimens ([Figure 3A](#f3-cmar-10-3697){ref-type="fig"}). Univariate analysis of clinical characteristics of 36 patients indicated that *VSIG4* expression was significantly correlated with tumor size and AFP level ([Table 2](#t2-cmar-10-3697){ref-type="table"}). The expression level of *VSIG4* was negatively related to the largest diameter of tumor (*p*=0.002) ([Figure 3B](#f3-cmar-10-3697){ref-type="fig"}) and serum level of AFP (*p*=0.011) ([Figure 3C](#f3-cmar-10-3697){ref-type="fig"}), which indicated a relationship between VSIG4 and prognosis of HCC patients.

Relationship between VSIG4 expression and prognosis of HCC patients
-------------------------------------------------------------------

All the 36 patients with HCC were clinically followed up for \>1 year. The DFS of the patients with low *VSIG4* expression was not significantly different from that with high *VSIG4* expression ([Figure 4A](#f4-cmar-10-3697){ref-type="fig"}). But in the HCC patients with HBV infection, the DFS of patients with low *VSIG4* expression was significantly shorter than those with high *VSIG4* expression ([Figure 4B](#f4-cmar-10-3697){ref-type="fig"}), which was consistent with the conclusion verified from TCGA data. HBV-positive HCC patients with low *VSIG4* expression had poor prognosis, which suggested that *VSIG4* was a potential tumor suppressor gene in HBV- related HCC.

Discussion
==========

HCC is one of the most common and aggressive malignant tumors with poor clinical outcomes. The conventional clinical stage classification systems are helpful in predicting the prognosis of the patients with different pathologic types.[@b18-cmar-10-3697] However, due to the high heterogeneity of HCC, further research should be undertaken to seek novel factors that could predict the prognosis of HCC more effectively. In this study, we investigated the expression of VSIG4 in HCC, and assessed its function in predicting the outcome of HCC patients. We demonstrated that low VSIG4 expression was closely associated with poor prognosis of HCC patients, especially in those with HBV infection.

VSIG4 is a member of the B7 family-related protein which is well known for its inhibition of T-cell activation and works as a coinhibitory ligand that inhibits T-cell activation and cytokine production through cell cycle arrest at the G0/G1 phase and induces T-cell anergy.[@b19-cmar-10-3697] In previous research, it has been reported that VSIG4 can regulate the tumor microenvironment and promote the proliferation, invasion, and migration of breast cancer cells, which indicates that VSIG4 also makes a significant contribution to the development and progression of the tumor.[@b10-cmar-10-3697] Additionally, VSIG4 expression in ovarian cancer tissues was lower in advanced and recurrent ovarian cancer, which suggested that VSIG4 can weaken the malignancy of the tumor.[@b11-cmar-10-3697] Furthermore, VSIG4 acting as the immune checkpoint molecule can be used as an independent prognostic factor for multiple myeloma and high-grade glioma.[@b12-cmar-10-3697],[@b13-cmar-10-3697] However, the expression of VSIG4 and its association with clinicopathological characteristics in HCC remain unknown. In our study, we demonstrated that *VSIG4* mRNA was downregulated in HCC by bioinformatics analysis, and low expression level of *VSIG4* was closely related to high serum AFP level and tumor distance recurrence, which indicated poor prognosis of HCC patients. Moreover, we explored *VSIG4* expression in 4 HCC cell lines and 36 pairs of tissue specimens in our center, and the results of the PCR assay were consistent with bioinformatics analysis. These results suggested that *VSIG4* gene functioned as a tumor suppressor gene in HCC.

To date, the underlying mechanism of VSIG4 in HCC remains uncertain. It has been reported that VSIG4 knockout mice showed severe hepatitis in liver injury animal models.[@b20-cmar-10-3697] Thus, we speculated that there may exist a certain relationship between hepatitis and VSIG4 in the aspect of HCC pathogenesis.

Hepatitis B infection is also a reason for HCC. Previous studies have confirmed that the viral load of hepatitis B is a risk factor for HCC development in chronic hepatitis B (CHB) patients, and viral suppression could slow the progression of HCC.[@b21-cmar-10-3697] Another related study[@b22-cmar-10-3697] demonstrated the relation between TIP30 expression and HBV infection and proved that TIP30 was an independent poor prognostic factor for the OS of HCC patients. Our study found that OS and DFS were not significantly associated with *VSIG4* expression in all HCC patients, based on the clinical data from TCGA. However, it is noteworthy that, in the subgroup of HBV-related HCC patients, the OS and DFS of the patients with low *VSIG4* expression were shorter than in those with high *VSIG4* expression. Cox regression analysis showed that *VSIG4* expression was an independent prognostic factor for both OS and DFS. We also obtained the similar results in the HCC patients from our center that HBV-positive HCC patients with low *VSIG4* expression had shorter DFS. Nevertheless, *VSIG4* failed to predict the prognosis of the patients with HCV, the mechanism of hepatocarcinogenesis of which differs from HBV.[@b23-cmar-10-3697]

Taken together, our present study demonstrated that the low expression of VSIG4 was closely related to poor prognosis in HBV-positive HCC patients. However, VSIG4 expression has no markedly predictive significance in HBV- negative patients. Therefore, *VSIG4* gene might serve as a potential tumor suppressor gene and a novel biomarker for HBV-related HCC. As the exact underlying mechanism of VSIG4 in HCC remains uncertain, further studies concerning VSIG4 and HCC pathogenesis need to be performed.

Conclusion
==========

To our knowledge, this study represents a first report identifying that VSIG4 was downregulated in HCC. Decreased expression of VSIG4 is an independent poor prognostic factor in HBV-related HCC. We suggest that VSIG4 could be a novel potential biomarker for HCC patients with HBV infection.
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![The expression of VSIG4 in HCC.\
**Notes: (A)** VSIG4 mRNA expression in HCC and adjacent tissues of 50 patients from the TCGA database. **(B)** VSIG4 mRNA expression in HCC and adjacent tissues of 60 patients from the GEO database (GSE64041). **(C)** VSIG4 mRNA levels of HCC patients with high and low serum levels of AFP. **(D)** VSIG4 mRNA levels of HCC patients in M~0~ and M~1~ stage. Independent and paired *t*-test, ^\*^*P*\<0.05, ^\*\*^*P*\<0.01.\
**Abbreviations:** FPKM, Fragments Per Kilobase of transcript per Million; GEO, Gene Expression Omnibus; HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas; VSIG4, V-set and immunoglobulin domain containing protein 4.](cmar-10-3697Fig1){#f1-cmar-10-3697}

![Correlation between VSIG4 expression and survival of HCC patients.\
**Notes: (A)** Survival curves for OS of all HCC patients in TCGA. **(B)** Survival curves for DFS of all HCC patients. **(C)** OS curves of HCC patients with HBV infection. **(D)** DFS curves of HCC patients with HBV infection. **(E)** OS curves of HCC patients without HBV infection. **(F)** DFS curves of HCC patients without HBV infection. Log-rank test, ^\*\*^*P*\<0.01.\
**Abbreviations:** DFS, disease-free survival; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; OS, overall survival; TCGA, The Cancer Genome Atlas; VSIG4, V-set and immunoglobulin domain containing protein 4.](cmar-10-3697Fig2){#f2-cmar-10-3697}

![The expression of VSIG4 in hepatoma cell lines and tissue specimens.\
**Notes: (A)** VSIG4 differential expression in 36 HCC specimens in our center, compared with matched adjacent normal tissues. **(B)** VSIG4 expression in HCC patients in our center with large and small tumor size. **(C)** VSIG4 expression in HCC patients in our center with high and low serum AFP levels. **(D)** VSIG4 mRNA expression in 4 hepatoma cell lines and 1 normal liver cell line. Independent *t*-test, ^\*\*^*P*\<0.01.\
**Abbreviations:** HCC, hepatocellular carcinoma; VSIG4, V-set and immunoglobulin domain containing protein 4; T/N, means tumor vs normal tissues.](cmar-10-3697Fig3){#f3-cmar-10-3697}

![The prognosis of 36 HCC patients in our center with high and low expression of VISG4.\
**Notes: (A)** Survival curves of DFS for 36 HCC patients in our center. **(B)** Survival curves of DFS for HCC patients with HBV infection in our center. Log-rank test.\
**Abbreviations:** DFS, disease-free survival; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; VSIG4, V-set and immunoglobulin domain containing protein 4.](cmar-10-3697Fig4){#f4-cmar-10-3697}

###### 

Relationship between the VSIG4 expression and clinicopathological characteristics in HCC patients from TCGA database

  Clinicopathological characteristics   VSIG4 expression[a](#tfn1-cmar-10-3697){ref-type="table-fn"}   *P*-value[b](#tfn2-cmar-10-3697){ref-type="table-fn"}   
  ------------------------------------- -------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------
  Age (years)                                                                                                                                                  1.000
   ≤45                                  12                                                             12                                                      
   \>45                                 79                                                             79                                                      
  Gender                                                                                                                                                       0.873
   Male                                 63                                                             62                                                      
   Female                               28                                                             29                                                      
  Hepatitis virus infection                                                                                                                                    0.157
   HBV                                  29                                                             35                                                      
   HCV                                  8                                                              14                                                      
   No                                   54                                                             42                                                      
  Child--Pugh                                                                                                                                                  0.867
   A                                    75                                                             74                                                      
   B                                    11                                                             13                                                      
   C                                    5                                                              4                                                       
  Cirrhosis                                                                                                                                                    0.223
   Yes                                  31                                                             39                                                      
   No                                   60                                                             52                                                      
  AFP (µg/L)                                                                                                                                                   0.022[\*](#tfn3-cmar-10-3697){ref-type="table-fn"}
   ≤400                                 68                                                             80                                                      
   \>400                                23                                                             11                                                      
  TNM stage                                                                                                                                                    
   T~1~                                 53                                                             47                                                      0.708
   T~2~                                 18                                                             24                                                      
   T~3~                                 17                                                             16                                                      
   T~4~                                 3                                                              4                                                       
   N~0~                                 69                                                             73                                                      0.474
   N~1~                                 22                                                             18                                                      
   M~0~                                 66                                                             80                                                      0.009[\*\*](#tfn4-cmar-10-3697){ref-type="table-fn"}
   M~1~                                 25                                                             11                                                      
  Histological grade                                                                                                                                           0.770
   G1                                   9                                                              10                                                      
   G2                                   44                                                             48                                                      
   G3                                   38                                                             33                                                      

**Notes:**

The median expression level of VSIG4 was used as the cutoff. Low VSIG4 expression in each of the 92 patients was defined as a value below the 50th percentile. High VSIG4 expression in each of the 92 patients was defined as a value above the 50th percentile.

χ^2^ test,

*P*\<0.05,

*P*\<0.01.

**Abbreviations:** HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; TCGA, The Cancer Genome Atlas; VSIG4, V-set and immunoglobulin domain containing protein 4.

###### 

Correlation between VSIG4 expression and clinicopathological characteristics of 36 patients in our center

  Clinicopathological characteristics   VSIG4 expression[a](#tfn6-cmar-10-3697){ref-type="table-fn"}   *P*-value[b](#tfn7-cmar-10-3697){ref-type="table-fn"}   
  ------------------------------------- -------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------
  Age (years)                                                                                                                                                  0.310
   ≤45                                  1                                                              0                                                       
   \>45                                 17                                                             18                                                      
  Gender                                                                                                                                                       0.289
   Male                                 15                                                             17                                                      
   Female                               3                                                              1                                                       
  Hepatitis B antigen                                                                                                                                          0.423
   HBsAg (+)                            15                                                             13                                                      
   HBsAg (−)                            3                                                              5                                                       
  Child--Pugh                                                                                                                                                  0.833
   A                                    15                                                             16                                                      
   B                                    2                                                              1                                                       
   C                                    1                                                              1                                                       
  Cirrhosis                                                                                                                                                    0.182
   Yes                                  7                                                              11                                                      
   No                                   11                                                             7                                                       
  AFP (µg/L)                                                                                                                                                   0.007[\*\*](#tfn8-cmar-10-3697){ref-type="table-fn"}
   ≤400                                 6                                                              14                                                      
   \>400                                12                                                             4                                                       
  T stage                                                                                                                                                      0.735
   T~1~ and T~2~                        7                                                              8                                                       
   T~3~ and T~4~                        11                                                             10                                                      
  Tumor size (cm)                                                                                                                                              0.006[\*\*](#tfn8-cmar-10-3697){ref-type="table-fn"}
   ≤5                                   3                                                              11                                                      
   \>5                                  15                                                             7                                                       
  Vascular invasion                                                                                                                                            0.457
   Yes                                  6                                                              4                                                       
   No                                   12                                                             14                                                      
  Histological grade                                                                                                                                           0.502
   G1 and G2                            11                                                             9                                                       
   G3                                   7                                                              9                                                       

**Notes:**

The median expression level of VSIG4 was used as the cutoff. Low VSIG4 expression in each of the 18 patients was defined as a value below the 50th percentile. High VSIG4 expression in each of the 18 patients was defined as a value above the 50th percentile.

χ^2^ test,

*P*\<0.01.

**Abbreviation:** VSIG4, V-set and immunoglobulin domain containing protein 4.

[^1]: These authors contributed equally to this work
